Condition

Acute hepatitis C

Clinical trials and treatment information for Acute hepatitis C

809K
People Affected
8
Active Trials
2M
New Cases/Year
5,474
Deaths/Year

Treatment Rankings

Ranked by evidence volume first. Medicine has spent centuries ranking things by vibes. This is an improvement.

1
Glecaprevir/Pibrentasvir
99% Effectiveness• 95% Confidence• 70% Safety• 3 trials• 8K participants
HIGH EvidenceExcellent ValueDose: 300 mg glecaprevir / 120 mg pibrentasvir once daily
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe

Time to Effect

Within 8 weeks of treatment completion

Duration

8 weeks

Response Rate

99%

Remission Rate

99%

Number Needed to Treat (NNT)

1

Number Needed to Harm (NNH)

100

Common Side Effects:

Headache: 19%
Fatigue: 14%
Nausea: 9%
Diarrhea: 6%

Annual Cost of Care

Drug Cost

$18,000

Monitoring

$1,000

Side Effects

$200

Total Annual

$19,200

Cost-Effectiveness

EXCELLENT

QALYs Gained

3

ICER

$45,000/QALY

Cost per Remission

$19,394

Cost per Responder

$19,394

Treatment Outcomes
Primary Outcomes
Hepatitis C Virus RNA LevelAverage 1,000,000 IU/mL
-100% (To undetectable (<15 IU/mL))
Alanine Aminotransferase (ALT) LevelAverage 150 IU/L
-80% (-120 IU/L (to normal range))
Aspartate Aminotransferase (AST) LevelAverage 100 IU/L
-70% (-70 IU/L (to normal range))
Secondary Benefits
Total Bilirubin LevelAverage 2.5 mg/dL
-60% (-1.5 mg/dL (to normal range))
Fatigue Assessment Scale (FACIT-F)Average 30/52
+33.3% (+10 points (indicating improved energy))
SF-36 Physical Component Summary ScoreAverage 40/100
+25% (+10 points (indicating improved physical health))
Common Side Effects
Headache
+19%
Fatigue
+14%
Nausea
+9%

Clinical Trial Phases:

Phase 3Phase 4
2
Sofosbuvir/Velpatasvir
98% Effectiveness• 95% Confidence• 70% Safety• 1 trials• 10K participants
HIGH EvidenceExcellent ValueDose: 400 mg sofosbuvir / 100 mg velpatasvir once daily
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe

Time to Effect

Within 12 weeks of treatment completion

Duration

8-12 weeks

Response Rate

98%

Remission Rate

98%

Number Needed to Treat (NNT)

1

Number Needed to Harm (NNH)

100

Common Side Effects:

Headache: 21%
Fatigue: 18%
Nausea: 11%
Diarrhea: 6%

Annual Cost of Care

Drug Cost

$25,000

Monitoring

$1,000

Side Effects

$200

Total Annual

$26,200

Cost-Effectiveness

EXCELLENT

QALYs Gained

3

ICER

$50,000/QALY

Cost per Remission

$26,735

Cost per Responder

$26,735

Treatment Outcomes
Primary Outcomes
HCV RNA Viral Load (at SVR12)6,000,000 IU/mL
-99.999% (Reduction to undetectable (<15 IU/mL))
Alanine Aminotransferase (ALT)200 IU/L
-85% (-170 IU/L)
Aspartate Aminotransferase (AST)150 IU/L
-83% (-125 IU/L)
Fatigue Score (FACIT-Fatigue Scale)20/52 (severe fatigue)
+75% (+15 points)
Secondary Benefits
FIB-4 Index1.8
-44% (-0.8)
SF-36 Physical Component Summary (PCS)38
+26% (+10 points)
Total Bilirubin2.5 mg/dL
-64% (-1.6 mg/dL)
Common Side Effects
Headache
+21%
Fatigue
+18%
Nausea
+11%

Clinical Trial Phases:

Phase 3Phase 4
3
Sofosbuvir/Ledipasvir
97% Effectiveness• 95% Confidence• 70% Safety• 3 trials• 8K participants
HIGH EvidenceGood ValueDose: 400 mg sofosbuvir / 90 mg ledipasvir once daily
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe

Time to Effect

Within 8-12 weeks of treatment completion

Duration

8-12 weeks

Response Rate

97%

Remission Rate

97%

Number Needed to Treat (NNT)

1

Number Needed to Harm (NNH)

100

Common Side Effects:

Headache: 19%
Fatigue: 15%
Nausea: 8%
Diarrhea: 5%

Annual Cost of Care

Drug Cost

$22,000

Monitoring

$1,000

Side Effects

$200

Total Annual

$23,200

Cost-Effectiveness

GOOD

QALYs Gained

2.8

ICER

$60,000/QALY

Cost per Remission

$23,918

Cost per Responder

$23,918

Treatment Outcomes
Primary Outcomes
HCV RNA (Viral Load)Typical range 10^5-10^7 IU/mL (e.g., 5,000,000 IU/mL)
-99.9997% (Reduction to undetectable (<15 IU/mL))
Probability of HCV Viremia (12 weeks post-treatment)100% (at diagnosis, patient is viremic)
-100% (Reduction from 100% to 0% viremia (achieving SVR12))
Alanine Aminotransferase (ALT)Typical range 50-200 U/L (e.g., 150 U/L)
-75% (-112.5 U/L (normalization, e.g., to 37.5 U/L))
Aspartate Aminotransferase (AST)Typical range 40-150 U/L (e.g., 100 U/L)
-70% (-70 U/L (normalization, e.g., to 30 U/L))
Secondary Benefits
Fatigue Severity Scale (FSS) Score5.5/7 (higher score indicates more severe fatigue)
-30% (-1.65 points)
SF-36 Physical Component Summary (PCS) Score40 (lower than general population average of 50)
+15% (+6 points)
Total Bilirubin2.0 mg/dL (elevated, normal <1.2 mg/dL)
-60% (-1.2 mg/dL (normalization, e.g., to 0.8 mg/dL))
Common Side Effects
Headache
+19%
Fatigue
+15%
Nausea
+8%

Clinical Trial Phases:

Phase 3Phase 4
4
Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir
96% Effectiveness• 90% Confidence• 65% Safety• 1 trials• 5K participants
HIGH EvidenceGood ValueDose: Two O/P/R tablets once daily + one Dasabuvir tablet twice daily
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe

Time to Effect

Within 12 weeks of treatment completion

Duration

12 weeks

Response Rate

96%

Remission Rate

96%

Number Needed to Treat (NNT)

1

Number Needed to Harm (NNH)

50

Common Side Effects:

Fatigue: 21%
Nausea: 11%
Insomnia: 9%
Pruritus: 6%
Elevated liver enzymes: 4%

Annual Cost of Care

Drug Cost

$22,000

Monitoring

$1,200

Side Effects

$300

Total Annual

$23,500

Cost-Effectiveness

GOOD

QALYs Gained

2.7

ICER

$80,000/QALY

Cost per Remission

$24,479

Cost per Responder

$24,479

Treatment Outcomes
Primary Outcomes
HCV RNA Viral Load (at SVR12)6,000,000 IU/mL
-99.999% (To undetectable (<15 IU/mL))
HCV RNA Viral Load (at End of Treatment)6,000,000 IU/mL
-99.999% (To undetectable (<15 IU/mL))
Alanine Aminotransferase (ALT)400 U/L
-90% (-360 U/L)
Aspartate Aminotransferase (AST)350 U/L
-88.6% (-310 U/L)
Secondary Benefits
Total Bilirubin2.5 mg/dL
-68% (-1.7 mg/dL)
Fatigue (FACIT-Fatigue Scale)35/52
+34.3% (+12 points)
Quality of Life (SF-36 Physical Component Summary)40 points
+20% (+8 points)
Common Side Effects
Fatigue
+21%
Nausea
+11%
Insomnia
+9%

Clinical Trial Phases:

Phase 3Phase 4
5
Daclatasvir + Sofosbuvir
95% Effectiveness• 90% Confidence• 68% Safety• 30 trials• 6K participants
HIGH EvidenceGood ValueDose: Sofosbuvir 400 mg once daily + Daclatasvir 60 mg once daily
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
68
DangerousModerateSafe

Time to Effect

Within 12-24 weeks of treatment completion

Duration

12 weeks

Response Rate

95%

Remission Rate

95%

Number Needed to Treat (NNT)

1

Number Needed to Harm (NNH)

100

Common Side Effects:

Headache: 18%
Fatigue: 12%
Nausea: 7%
Diarrhea: 4%

Annual Cost of Care

Drug Cost

$12,000

Monitoring

$1,000

Side Effects

$200

Total Annual

$13,200

Cost-Effectiveness

GOOD

QALYs Gained

2.5

ICER

$75,000/QALY

Cost per Remission

$13,895

Cost per Responder

$13,895

Treatment Outcomes
Efficacy Outcomes
Overall Effectiveness
+95%
Response Rate
+95%
Remission Rate
+95%
Common Side Effects
Headache
+18%
Fatigue
+12%
Nausea
+7%

Clinical Trial Phases:

Phase 3Phase 4